96 Bevacizumab-Based Anti-Tumoral Therapy Does Not Increase the Risk of Bowel Perforation in Patients With Metastatic Obstructive Colorectal Cancer Palliated With Self-Expanding Metallic Stents. Results of a Prospective Study

MLA

Giovanni Rossi, et al. “96 Bevacizumab-Based Anti-Tumoral Therapy Does Not Increase the Risk of Bowel Perforation in Patients With Metastatic Obstructive Colorectal Cancer Palliated With Self-Expanding Metallic Stents. Results of a Prospective Study.” Gastrointestinal Endoscopy, vol. 81, May 2015, p. AB111. EBSCOhost, https://doi.org/10.1016/j.gie.2015.03.002.

APA

Giovanni Rossi, Paolo Delrio, Cristina Bucci, Daniela Rega, Guglielmo Nasti, Andrea Belli, Mario De Bellis, Elena Di Girolamo, F. Bianco, Leonardo Frazzoni, Valeria Vicario, Antonio Avallone, & Lorenzo Fuccio. (2015). 96 Bevacizumab-Based Anti-Tumoral Therapy Does Not Increase the Risk of Bowel Perforation in Patients With Metastatic Obstructive Colorectal Cancer Palliated With Self-Expanding Metallic Stents. Results of a Prospective Study. Gastrointestinal Endoscopy, 81, AB111. https://doi.org/10.1016/j.gie.2015.03.002

Chicago

Giovanni Rossi, Paolo Delrio, Cristina Bucci, Daniela Rega, Guglielmo Nasti, Andrea Belli, Mario De Bellis, et al. 2015. “96 Bevacizumab-Based Anti-Tumoral Therapy Does Not Increase the Risk of Bowel Perforation in Patients With Metastatic Obstructive Colorectal Cancer Palliated With Self-Expanding Metallic Stents. Results of a Prospective Study.” Gastrointestinal Endoscopy 81 (May): AB111. doi:10.1016/j.gie.2015.03.002.